<DOC>
	<DOCNO>NCT02042781</DOCNO>
	<brief_summary>This Phase Ia study aim establish maximum tolerated dose once-weekly IV infuse PG545 evaluate safety subject advance solid tumour . In addition , study explore whether PG545 exposure result change chemical produce body associated cancer growth spread .</brief_summary>
	<brief_title>Study Safety Tolerability IV Infused PG545 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age &gt; =18 year . Histological cytological documentation non hematologic , malignant solid tumour . Have fail least one previous therapeutic regimen . LIfe expectancy &gt; = 12 week . ECOG performance status 0 1 . Written , sign date informed consent . Able willing meet protocolrequired treatment , investigation visit . Have adequate organ function . Clinically significant nonmalignant disease . Active CNS metastasis . Subjects uncontrolled diabetes . History clinically significant adverse drug reaction heparin anticoagulant agent Concomitant use aspirin ( &gt; 150 mg/day ) , NSAIDs ( except COX2 selective inhibitor ) , vitamin K antagonist ( lowdose ) , heparin within two week prior randomisation , antiplatelet drug . History severe allergic , anaphylactic significant adverse reaction radiographic contrast medium . Known seropositivity human immunodeficiency vies ( HIV ) Women pregnant breast feed Women childbearing potential male subject partner woman child bear potential unable unwilling use effective mean contraception . Subjects receive investigational agent within 28 day prior Cycle 1 Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PG545</keyword>
	<keyword>Phase I</keyword>
	<keyword>Progen</keyword>
	<keyword>antimetastatic</keyword>
	<keyword>antiangiogenic</keyword>
	<keyword>advanced cancer patient</keyword>
	<keyword>solid tumor</keyword>
	<keyword>solid tumour</keyword>
	<keyword>tumor microenvironment</keyword>
</DOC>